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The urinary corticoid excretion of patients suffering from dys­
trophia myotonioa, syotonia congenita, rheumatoid arthritis and dis­
seminated lupus erythematosus was determined before, during and after 
hormonal therapy. The hormones administered were 17-hydroxy-11- 
dehydrocorticosteron®, pregnenolone, dehydroisonandrosterone and the 
adrenoeorticotrophic hormone. The Corcoran and Page method was used 
to determine the excretory levels.
In each of the three patients suffering from dystrophia myotonica 
whose excretory levels were determined during and after treatment with 
ACTH, a definite adrenal cortical response was noted. In five of the 
six patients suffering from dystrophia myotonlca and ayotonia congenita, 
an improvement in myotonia was realised. It is hoped from this evidence 
that the adrenocortlicotrophic hormone may offer some benefit in the 
treatment of these diseases.
Two patients suffering from rheumatoid arthritis and one from 
disseminated lupus erythematosus showed no clinical response to treat­
ment with massive doses of pregnenolone or dehyrdroisoandrosterone. How­
ever, in three of the four series involved, the pattern of cortlcoid 
excretion was similar to that noted when the adrenal cortex is under 
stress. It was postulated that the hormones might be converted into 
non-active corticoids or that they might produce a stress on the
adrenal cortex.
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URXHAF.X CORTICOIDS AFTER ADMINISTRATION OF ADRSSOCORTICOrROPHIC 
HORMONE, CORTISONE, ARTISONB OR DEHXBROISOANDRQSTMONE
Interest was focused on the function of the adrenal cortex in 
1855 when Thomas Addison, studying anemias, described a universally 
fatal type associated with a characteristic set of symptoms and re­
lated to hypofunction of the adrenal cortex.
It has been demonstrated repeatedly that removal of both 
adrenals is fatal and that the resulting symptoms are due to lack 
of cortical tissue. In 1927, Hartman, MacArthur and Hartman (1) 
demonstrated that adrenaleetomised cats could be maintained by injec­
tions of an extract of cortical tissue. The nature of the hormones 
involved in life maintenance has now been elucidated by extractions 
and isolation, chemical identification and synthesis of the hormones.
Myers, Mason and Kendall (2), in attempting to Identify sub­
stances extracted from the adrenal cortex, related the structure of 
»cortlnw and other steroid hormones to cholesterol, thus opening the 
way to the us# of a large number of classification tests known for 
plant and animal sterols. From their bensene-water fractionation 
they separated three mixed crystalline substances from which they 
Isolated and identified a number of steroid compounds. Simultaneous 
investigations by Reichstein, by Wintersteiner and Pfiffner, and by 
Gartland and Kuisenga contributed to the classification and identifica­
tion of these compounds. Reichstein (3) has reviewed this work.
Sarett (1*5 confirmed the structural formula of the cortical hormones 
by a partial synthesis of 17-hydroxy-ll-debydrooorticosterose. He 
used desoxy cholic acid a® a starting material and identified
2intermediates.
From the combined efforts of these men k3 compounds were Isolated 
and identified fro® the adrenal cortex. Curing the past few years,
Mason and Sprague (5) succeeded in isolating 17-hydroxy-cortieosteron® 
from the urine of a patient with Dashing1s Syndrome associated with 
severe diabetes raellitus. Mason (6) later isolated 17-hydroxy-ll- 
dehydrocorticostercne from two Addisonian patients maintained on that 
hormone, and he also isolated 17-hydro*ycorticost*rone and 17-hydroxy- 
11-debydrooortieosterone from four patients whose rheumatoid arthritis 
was treated with these hormones. Small amounts of a compound pre­
sumably 17-hydroasy-ll-dehydrocorticosterane were isolated fro® normal 
urine but positive identification was prohibited by the paucity of 
the yield. Schneider (7), by chromatographic analysis isolated
of 17-hydroxy-H-dehydrocorticGSterone fro® normal male
urine.
Of these 3 eospound© isolated fro® the adrenal cortex, six were 
shown to have physiological activity simulating in part adrenal cortical 
extracts. These six (listed and structural formulas given in Chart I) 
were noted to have in coistaon, beside the cyclopentanophenanthren® 
nucleus eosaaon to all forty-three, a 3-k®to group and double bond, 
a 20-keto grotp and a 21-hydroxyl group. Evidences that these three 
characteristics are essential to the physiological activity of these 
compounds includes the fact that reduction at any emu of these positions 
destroys the physiological activity of the compound.
The amorphous material left after the extraction of these 
compounds fro® the adrenal cortex has been found to be more active in
3STRUCTURAL FORMULAS OF ABREMAL CORTICAL HORM08ES 
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hlif® maintenance then any of them but little is known of its compo­
sition.
These compounds which do not exhibit physiological activity 
have generally been assumed to be precursors or break-down products
of the active hormones* or to be the result of the chemical manipu­
lation during the extraction process. In the part of this paper 
dealing with hormone metabolism the evidence supporting these con­
clusions is discussed.
In order to evaluate the ability of an adrenal cortical substance 
to protect the adrenalectomlzed animal against deficiency symptoms 
biological assays were developed depending on the ability of a sub­
stance to replace in some manner excised tissue. Since each test 
measures protection against only a portion of the total deficiency 
it is necessary to conduct several tests in order to establish the 
potency of a compound.
The six hormones known to be active in combating some of the 
effects of adrenalectoiqr divide themselves into two general classifi­
cations. Those having an oxygen in the C-ll position affect carbo­
hydrate and protein metabolism and offer protection to the adrea- 
alectomised animal against the deleterious effects of exposure to cold* 
prolonged muscle stimulation, decrease in the deposition of liver 
glycogen * and utilisation of alanine and pyruvic acid as glycogen 
formers. They are sometimes referred to as the S-horaones because 
of their effect on sugar metabolism.
Those which do not contain an oxygen in the C*U position are 
active in maintaining the adrenaleetomised animal in normal electro-
5lyte balance, i.e., they decrease the excretion of sodium, chloride 
and water and decrease the excretion of potassium. The hormone® of 
this group are able to maintain an adrenalectomised animal in an 
tiv e condition and normal with respect to appearance, clinical signs, 
appetite, and blood nitrogen levels. Era addition they enable the 
adrenalectoaised animal to react normally to short time muscle stimu­
lation.
Carnes, Ragen, Ferrebee and O'Neill (8) established the fact that 
desoxyeorticosterone may play a prominent role among the hormones of 
the adrenal cortex by demonstrating that its continual administration 
to rats resulted in atrophy of the adrenal cortex.
Survival time of adrenalectomiaed animals is prolonged by the 
administration of any of these hormones, or more effectively by a 
combination of several, by adrenal cortical extract, or by the amor­
phous fraction which remains after extraction* Progesterone in very 
large doses is also active in increasing survival time.
The significance of the biologically active compounds of the 
adrenal cortex to human beings has been demonstrated by con$>ariaon 
of the urinary excretion of cortlcolda, determined both biologically 
and chemically, of normal persona, of persons suffering from hypo- 
function of the adrenal gland or anterior pituitary gland, and of 
persons suffering from hyperfunction of either gland due to hyper­
plasia or tumors.
Treatment of Addisonian patients with adrenal cortical hormones 
confirms their biological activity and shows them to have reactions 
similar to those found in animal experiments. The maintenance of
6Addisonian patients in till* way is a well established clinical procedure.
Thorn, Garbutt, Hitchcock, and Hartman {9) demonstrated that 
adrenal cortical extract administered to either normal persons or those 
suffering from adrenal cortical deficiency resulted in reduction of 
sodium and chloride excretion, Increased elimination of potassium, 
Increased plasma volume and decreased blood non-protein-nitrogen level.
Thom, Howard and Emerson (10) maintained an Addisonian patient 
on a salt free diet in order to evaluate the Influence of desoxy- 
cortieosterone on both the clinical condition and laboratory findings 
of the patient. They found it permitted the patient to gain weight 
and that there was an increase in blood pressure and plasm volume.
Blood sodium, chloride and potassium levels return®! to normal, and a 
positive sodium and chloride balance was maintained. There was also 
an increase in urinary excretion of phosphorus, improved muscle 
strength, and a feeling of well-being. Withdrawal of the medication 
resulted in the reestablishment of all these deficiency symptoms, and 
resumption of treatment produced changes similar to those following 
the original administration.
One method of evaluating the functional state of the adrenal 
cortex is by measuring the urinary excretion of eortln. The biological 
activity of these compounds has permitted the development of bioasaay 
methods for the determination of their excretory levels. Of these 
methods, the stimulation of liver glycogen deposition in adrenalectomlsed 
rata is perhaps toe most commonly used (11).
However, chemical testing is largely replacing biological testing 
where possible, because of toe relative ease of manipulation and the
Tstricter control possible as adequate testing procedures are dereloped.
The term "cortin" has come into ua® to denote those compounds pro­
duced by the adrenal cortex which have a 20-keto and a 21-hydroxyl 
group, thus excluding the androgenic compounds which are probably pro­
duced by the adrenal cortex. The corfcin fraction is determined by 
methods based on the reducing ability of this characteristic group.
The existence of the carbonyl group in these compounds suggested 
the possibility of testing procedures baaed on the reducing action 
of this characteristic group aid early procedure® utilised variations 
of folin‘8 (12) blood sugar technique.
Reichstein (13) found that formaldehyde was produced by the 
oxidation of cortin compounds and Lowensteln, Corooran and Page (Hi) 
developed a colorimetric method for determining the amount of 
formaldehyde released.
A distillation procedure to eliminate certain non-specific 
chromogenie materials was introduced by Daughaday, Jaffa and Williams (15).
Corcoran and Page (16) modified the Daughaday, Jaffa and 
Williams procedure and an earlier procedure of their own to include 
controls that would eliminate error due to chromogenlc material in 
the reagents and non-specific chromogenlc material In the wine 
samples. This latter procedure was utilised in this work.
Venning and Browne (1?) utilised their bioassay technique based 
on glycogen deposition in the liver to determine the level of excre­
tion of cortical hormones of normal persona and those suffering from 
clinical disorders related to the adrenal cortex. Their unit was the 
amount of a substance which is equivalent in biological activity to
31 mtcrogram of 17-hydroay-ll debydrocorticosterone in increasing lirer 
glycogen deposition in adrenaleetorai*ed rat. Chart 2 shows their re­
sults.
SEX CLINICAL CONDITIO! AGE CQRTIM LEVEL
Female Normal 21-H8 units
CHART 2
Male Normal 20-51 60 units
Male Addisonian 28 < 10 units
Female Addisonian 56 < 10 units
Female Addisonian 29 4 10 units
Female Addisonian 39 15 units
Male Pan hypopituitarism hB ( 10 units
Male Pan hypopituitarism 32 13 units
Male Pan hypopituitarism la < 10 units
Female Pan hypopituitarism us <10 units
Male Pan hypopituitarism h i < 10 units
Male Cushing’s Syndrome 33 600 units
Female Cushing’s Syndrome U2 316 units
Male Cushing’s Syndrom 11 386 units
Female Cushing’s Syndrome 39 137 units
Male Cushing’s Syndrome* 27 h2 units
xo
E. D. H. Beard (18) has gives a summary of the work of Vanning 
and associates (19, 20, 21), that of Heard, Sobel and Venning (22), 
and that of Talbot, Saltsman, Wixom and Wolfe (23), all of who® 
used chemical procedures to determine the levels of corticoid a*sr®~ 
tion. Their findings are similar in comparing normal persons with 
those having hypo or hyperfunction of the adrenal cortex. Their 
results are shown in the Chart 3, which is a part of a table presented 
by Heard.
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CHART 3
lypi of
Subject
HiSTigrams excreted pier Si hours 
Cortis Reducing Substances 
Penning #1 Seard "' faXbof
Horaal female
average
0.035? 1.3 0.2h
Korsjal male 0.062 1.5 0.2lj
Rypcfunction 
Addison's Disease o-o.oiS 0.02-0.26
Panhypopituitarism 0 04-0.6 0.10-0.17
Ryperfunction
Hirsutism o.o5o-o.o65 0.23-0.32
Cushing's Disease 0.2-0.7 luS 0.90-12.0
Virilism 0.15-0.57
Stress
Burns o.1-0.5 3.04.0 0.3b-1.70
Postoperative 0.1-0.2 0.3h-1.70
Late pregnancy 0.1-04 2.8-3.2
Aa Kendall's Compound B
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As has been noted above, early investigation concerning the 
function of the adrenal cortex dealt largely with results of cortical 
deficiency. Some relationship was demonstrated between certain, 
clinical conditions and hyperfunction of the adrenal cortex (Cushing's 
■Syndroms and the adrenogenital syndrom).
In 1937, a different approach to adrenal cortical function was 
introduced by Mans Selye (2k) who described a condition in experimental 
animals which he called the Adaptation syndrome. This reaction, which 
was associated with the development of resistance to many types of 
stress, was a phenomenon which he attributed to stimulation of the 
adrenal cortex.
At about the same time and related to this work, Selye and Hall 
administered large doses of desoxycorticosterone to experimental ani­
mals and produced histological changes which simulated those seen in 
many chronic disease processes.(25).
This work, together with many other observations, led to the be­
lief that the adrenal cortex was involved in some phase of metabolism 
other than those obvious from the result of studies of adrenal 
deficiencies.
As the result of his observations that rheumatic disorders improved 
in clinical states which could be possibly associated with either 
increased production of corticosteroids or their accumulation for some 
other reason, Hench (26) demonstrated that the administration of large 
doses of l?-hydroxy-ll-debydrocortlcosterone (Compound E or cortisone) 
would give relief in rheumatoid arthritis, an observation which has 
now been extended to many other diseases. This led to a new concept
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regarding the function of the adrenal cortex which is at present under 
intense investigation and has not as yet been fuUy elucidated.
The dosage of these hormones usually administered is thought to ex­
ceed greatly the amount produced by the adrenal cortex. No way of 
measuring directly the level of secretion of the adrenal cortex is 
known, however. It might be expected that such massive doses of 
the adrenocorticotrophic or adrenal hormones would elliclt a response 
similar to that following the hypersecretion of hormones due to 
stress or to C’udiirg *s Syndrome. This expectation has been only 
partially realized.
Sprague, Power, Mason, Albert, Mathieson, Bench, Kendall, Slocum 
and Polley (27) in a review of patients they have treated, report that 
in almost every case benefit, at least of a temporary nature was realised. 
However, the effects they noted to be induced by these hormones in 
certain of these patients included acne, hirsutism, effects on men­
struation, effects on glutathione levels, euphoria, depression, asthenia 
and. a condition simulating diabetes mellitus.
Mason, Power, Eynearson, Ciaramelli, Li aid Evans (28) found no 
significant change in the sodium, potassium, chloride, phosphorus, 
red blood cells, white blood cells, or electrophoretic pattern of 
the plasma proteins following administration of adrenocorticotropic 
hormone to a normal human being. Stimulation of the adrenal cortex 
was evidenced in this experiment by significant increase in urinary 
excfetion of androsterone, etiochloanone and pregnanediol.
Mason and Kepler (29) found an increase in androsterone and 
and etiocholanone which amounted to as much as forty-three per cent of
an administered dose of 100 mg. dehydroisoandrosierone per twenty-four 
hours to a normal human being. The similarity of the excretory pro­
ducts in these two cases suggests the possibility that dehydroiso- 
androsterone might enter the metabolic reaction at such a stage that 
it could produce effects similar to the adrenocortiootrophic hormone 
(hereinafter ACTE) injections, and thereby bestow the benefits of 
ACTS while possibly avoiding some of the complications encountered.
The fact that dehydroisoandrosterone excretion is known to be 
increased to as much as one hundred times the normal amount in some 
adrenal cortical tumors lends further support to this concept.
Another compound which has been Investigated in the hope that it 
might enter the metabolic chain and which has been reported by David­
son, Koets, Snow and Oabrielson (30) to be of benefit to arthritic 
patients is 5-pregnenolone (artisone). This compound, an oxidation 
at the C-l? position yields dehydroisoandrosierone.
The treatment of persons suffering from conditions not known to 
result from the lack of functioning adrenal cortical tissue Is now in 
its infancy. Basic to the development of such therapy is the work of 
Collip, Anderson, and Thompson (31) who isolated a substance from the 
anterior pituitary which could stimulate the growth of the adrenals 
in hypophysectoaized rats. Smith and Engle (32) transplanted the 
anterior pituitary of rats into immature rats and induced precocious 
maturity, thus demonstrating the function of the anterior pituitary 
in regulating the activity of another gland.
Li, Evans and Simpson (33) isolated the adrenocorticotrophlo hor­
mone from the pituitariea of sheep, purified it and demonstrated
15
its ability to stimulate secretion by the adrenal cortex by dogs.
Subsequently, Armour and Company have developed production methods 
that have enabled them to make large quantities of the adrenocortico- 
trophic hormone available. This has made possible the extensive re­
search now in progress as well as the treatment of a large number of 
patients.
It is important to understand the mechanism of the improvement 
of the patients who have benefited so markedly from treatment with 
these hormones. In order to understand this improvement it is 
necessary to determine which of the two danger periods in the "alarm 
reaction" described by Selye (2h) is related to the chronic diseases 
under consideration. That isi during the stress period when conditions 
simulating the massive doses occur or during the exhaustive phase when 
massive doses may be necessary to assist the exhausted cortex.
Tremendous increases in circulating hormones have been shown 
to occur following such acute stimuli as burns, surgery, trauma, 
emotional strain and high feversj conditions which predispose an 
individual to the chronic diseases benefited by adrenal hormonal 
therapy. Ho consistent change in the level of cortin excretion has 
been demonstrated for persons suffering from chronic diseases. This 
may be because the patients are tested at varying levels of response, 
or because urinary excretion of cortin is not a reliable method for 
quantitating cortical activity.
It is also important to learn of the metabolic pathway of these 
hormones.
It was hoped that by determining pretreatment and treatment
16
levels of the persons in this series, some information on these two 
subj sets might be gained.
Eight of the persons in the series were suffering from dystrophia 
ayotonica or syotoala congenita. Ho adequate treatment is known for 
these diseases. The etiology of these diseases is unknown, but they 
are thought to be metabolic in nature. For these reasons, it was hoped 
they might fall in the category of those diseases which could be 
helped by adrenal cortical hormonal therapy, and at the same time 
some information regarding their etiology be gained.
Two persons with rheumatoid arthritis and erne with disseminated 
lupus erythematosus were included in the series. It was hoped they 
would be benefited by the extremely large doses of the horaoned ad­
ministered and that the cortical levels following suefc large doses 
would help to elucidate the metabolic pathway of the hormones used.
Fart of the treatment of these patients was with a representative 
of the C-19 (androgenic) group of hormones. Although treatment with 
this compound (dehydroisoandrosterone) and also with pregnenolone has 
been reported to be of benefit, no attempt has been made to determine 
whether the benefit might be of the result of their acting as the 
metabolic precursors of cortin.
Mason, Kepler and Schneider (3b) administered 150 mg. dehydroiso­
androsterone daily to a woman before and after removal of an adrenal 
cortical tumor. In either case they noted only a slight increase in 
17-ketosteroid excretion. They isolated androsterone, etioeholanone, 
pregnanediol, aadrostenediol, androstenediol, and dehydroisoandros­
terone from the urine. Consequently, the possibility exists that the
17
disappearance of dehydroiaoandrosterone is due to its acting as a 
precursor of the adrenal cortical hormones.
In summary the following studies wer© mades
(1). To determine whether ACTE was of benefit in dystrophia 
nyotonica and myotonia congenita, metabolic diseases in which it had 
not yet been tried.
(2). To determine whether pregnenolone was bsneficial in these 
conditions and, if so, if its benefit could be attributed to its 
metabolic transformation into cortin.
(3). To find whether dehydroisoandroeterone, the C*19 steroid 
could enter into the metabolic pathway and also be of benefit to these 
patients.
I
PURPOSE
The purpose of this work was to determine the eortin excretion 
of patients with rheumatoid arthritis, disseminated lupus ery­
thematosus, dystrophia myotonica and myotonia congenita before, 
during and after treatment with ACTH, eoapound I, detydrolsoandros- 
terone and pregnenolone.
19
Patientsi In this study the therapeutic agents ACTS, dehy- 
droisoandrosterone, pregnenolone and Coapound E were administered in 
the amounts and frequencies designated in the protocol for each 
individual patient. The length of the metabolic periods involved is 
given for each patient in the individual protocol.
Analytical Methods i Before, during and after the administra­
tion of the hormones, twenty-four urine specimens were collected and 
analysed for oortlcoida by the fonaaldehydogenic method of Baaghaday, 
Jaffa, and William (15) as modified by Corcoran and Page (16). This 
method was chosen because it is adaptible for use with small quantities 
of urine. In addition, this method seemed to have the following three 
advantages over other methods! (1) the oxidation and reduction solu­
tions wore titrated against one another to insure accurate control of 
these two important reagents, (2) the distillation step was included 
to prohibit certain non-specific chromogenic compounds from being 
present when the colorimetric reaction took place, (3) the use of
both an oxidised and an unoxidised urine blank reduced the probability
of errors das to chromogenic material in the urine samples which might
pass over in the distilling procedure.
METHODS
20
BEAOHHTS
Chloroform C.F. Chloroform was used. It was redistilled over 
glass, the head and tail fractions were discarded, 0.7$ per cent ab­
solute ethyl alcohol was added to inhibit the formation of phosgene, 
and it was stored in a dark bottle.
Wateri Triple distilled water was used In preparation of reagents 
and in analysing the dried residues.
Glacial acetic acid, hydrochloric acid, sodium bicarbonate, and 
sulfuric acid! C.P. reagents were used.
Periodic aoldt C.P. potassium periodate reagent was used and 
made as specified.
Stannous ohloridet C.P. stannous chloride reagent was used. It 
was made by dissolving l .h  grams stannous chlorids in 50 cc. 2.5 M 
hydrochloric acid and titrating against the periodic sold solution to 
a starch endpoint and adjusting so that 10.2 cc. periodic acid oxidised 
10 oc. chloride solution.
Chroatotropio acidi Eastman Kodak Cotqpany 1,8 dlhydrc«ynapbthalen@ 
sulfonic acid reagent was used and made as specified. Since no tins 
limit was specified, determinations done within approximately one 
hour were run on the same ehrom&tropie acid solution. The occasional 
repeated determinations indicated that this time span was permissible.
Extraction procedurei The extraction procedure varied in some 
details from the original method. The solvents used and the extraction 
times were different. Comparisons were made using the method described 
herein and the author’s method for the same urine sample. There were 
no significant differences observed.
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The extractions were carried out as follows« determinations were 
made from 2khour samples preserved by toluene and kept cold, and when­
ever possible, extracted within 1*8 hours. One hundred cubic centimeter 
aliquots were acidified with 50 per cent sulfuric acid to approximately 
pH 1, extracted with 100 cc., 60 cc., 1*0 ce. ohloroform. Emulsions 
were broken by centrifugation. The chloroform was then washed with 
50 cc. saturated sodium bicarbonate solution. This was followed by 
enough distilled water washes to adjust the pH to between six and 
seven, (in most oases three washings was sufficient). The chloro­
form fraction was removed under reduced pressure to about 10 cc. at 
1*0-50® Centigrade and this was transferred with chloroform washings 
to a small flask. The remainder was evaporated in an atmosphere of 
nitrogen under reduced pressure. The material extracted in this way 
was stored for from two to six months. When this method was compared 
to the extraction procedure originally described, no significant 
differences in results were encountered.
The dried residue in the flask was dissolved in 1.0 cc. of glacial
acetic acid and 17 cc. distilled water were added to it. The contents
were then divided into two equal portions, one to be used as an oxidised
sample, the other as a urine blank.
The oxidised'* sample was treated with 0.5 cc. periodic acid and 
oxidation was allowed to proceed at room temperature for thirty minutes. 
Oxidation was arrested by the addition of 0.5 cc. stannous chloride 
reagent.
The unoxldiaed sample was treated with 0.5 cc. stannous chloride 
reagent followed immediately by 0.5 cc. periodic acid.
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Oxidized and unoxidised blanks were prepared using distilled 
water in place of the solution of urinary extract.
Each sample was then transferred to an all-glass micro distilla­
tion apparatus with three one ce. water washings. It was distilled 
into one eo. of water in a centrifuge tube and the condenser outlet 
was placed under the surface of the water. About 8 ce. of distillate 
was collected and the volume was made tp to 10 ce. with distilled 
water.
Three cubic centimeters of distillate were transferred to a tall 
glass tube. Fire ml. of the chromotropic acid reagents were added and 
mixed immediately. The tube was placed in a boiling water bath for 
thirty minutes, rapidly cooled to 25° C., made up to 10 C. in a cold 
water bath.
The color density was determined at 570 millimicrons, reading 
oxidized sample against unoxidized blank.
Calculationsi The color density of the unoxidized sanpl® was 
subtracted from that of the oxidized sample. This gave the color 
density due to formaldehyde liberated from corticosteroid«llke sub­
stances in the urine and was compared to a predetermined curve for 
desoxycorticosterone and expressed as milligrams desoxycorticosterone 
per 2h hours.
Principlet This procedure is dependent upon the ability of the 
characteristic group of these hormones to be oxidised yielding formalde­
hyde. The resulting formaldehyde reacts with chronotropic acid to 
give a lavender color. The density of this color is proportional to 
the amount of formaldehyde generated. The density was measured by the
23
use of the Colemanphotoelectric colorimeter Model 11 and reported as 
milligrams deacaycortieosteroae equivalents excreted per twenty-four 
hoars.
Standard curvet The standard carve was prepared by using weighed 
portions of desoxycortiooaterone. Its coefficient of extinction 
determined to be .2b0t* and the factor relating density of color to 
milligrams deaaxycorticoaterone ,3125. Figure shows the standard 
carve obtained.
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STANDARD CURVE BASED ON DESOXYCQRTICOSTERONE
Micrograms Besoxycortieosterone/ec
Factor ■ density ■
raicrograms/cc
Coaf. of extinction a density
SCorograraa
lengro'Tpatir
HOKMLS
1.33 ag./2U hours 
1.2? ag./2h hours
1.31 ag./2h hours 
1.17 ag./2b hours
•952 ag./Si* hours 
.90S ag./2t; hoars
l.li* ag./2k hours 
1.21 ag./2l* hours
.928 ag./2it hours 
.95? ag./2b hours
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PATIEEfP #1
Age
S«K
Disease
Duration
i^ rsptoms
Treatment
Response
P atien t J.K.
50 years
Male
Dyatrophia ifrotonica
25 yeara
Alopeeia* cataracts, testicular 
atrophy, sever® generalised muscular 
atropfcy and myotonia of the hands.
ACTS 100 mg./day
5-27-50 to 6-3-50
Moderate improvement of the ayotonia
______Mature of Specimen Treatment
5-26
6-3
7-2h
Control
Treatment
Control
"aESrStlSj
per 2h hours
ISOM
100 mg./day
ACTH
none
.382 mg. 
.370 mg.
1.10 9%.
.739 mg* 
•639 mg.
21
ntimt  #2
Age
S«c
Disease
Duration
Symptoms
Patient Be Be
1*2 years 
Female
Dystrophia 2$rotonica 
Two year®
Cataracts, atrophy of hands and legs, 
and moderate ayotonia. Her condition 
at present is ailld and her disability 
only moderate. She is one of three 
in one family suffering from this 
disease.
Treatment She received no hormonal therapy.
Secretion
Date  Mature of Specimen Treatment______per 2t* hours
5-15 Control 1.80 mg.
2.05 mg.
5-16 Control none % 1,78 mg.
1.68 mg.
20
PATIF1IT #3
Age
Bex
Disease
Duration
Symptoms
Treatment
Patient G» B.
38 years 
Hale
Dystrophia f$rotoniea 
15 years
Alopecia, extreme cataracts, testicular 
atrophy, severe generalised muscular 
atrophy and moderate myotonia. He is the 
father of D.B. and brother of I.®-.
100 mg./2k hrs.ACTH 8-8-50 to 8-11-50
50 mg ./2khr s. ACTH 8-11-50 to 8-20-50
He showed definite improvement of myo­
tonia but no increase in strength.
''^ ere^ iori
Date nature of Specimen Treatment per 2l* hours
5-25
5-2?
7-28
8-20
Control
Control
Control
Treatment
none
none
none
50 »g./day
ACTH
.573 «g. 
.639 mg.
.31*8 mg.
1.65 mg. •1
.736 mg.
2.1*1 mg. *2
»1 See explanation at end of this section
*2 The volume of this sample is questionable
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pat: ™
Age
Sex
Disease
Duration
Symptom
P atien t
Treatment
Response
D.B.
9 years 
Male
Dystrophia Jtyotonlea 
k years
Insipient cataracts, atrophy of face, 
forearms, hands and legs, moderately 
severe mechanical and voluntary myo­
tonia widely distributed. He is the 
sisse of a six-year old and has had al­
most no increase in sis® since the 
onset of the disease.
SO mg. ACTH 6-8-50 to 8-18-SO
Moderate ia^roeemeat of myotonia and 
excellent evidence of adrenal cortical 
response.
Date Mature of Specimen Treatment Excretion*' per 2hours
7-20
8-20
Control
After treatment
none .158
.186 mg.
2.70 mg. 
2.86 mg.
30
PATHS? #5
\
Age .
Sex
Disease
Duration
Symptoms
Treatment
P atien t Q.S.
29 years 
Male
Dystrophia nyotonica 
5 years
He had no alopecia or cataracts. He 
had marked general myotonia and atrophy 
of the face and hands.
He underwent no hormonal therapy.
Date
5-6
5-6
5-8
5-8
5-9
5-9
Mature of Specimen Treatment
Control
Control
Control
Control
Control
Control
none
none
none
none
none
none
'SirsSoi
JEgJjJfegg&.
1.95 mg. 
1.38 mg. 
2.77 mg.
2.60 mg. 
.81*6 mg. 
.870 mg.
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PATIFMT #6
Patient
Age
Sex
Disease
Duration
Symptoms
Treatment
Response
L» S»
U8 years 
Male
Dystrophia Myotonlca 
30 years
Alopecia, testicular atrophy, cataracts, 
severe general atrophy, especially of 
to® back and lower extremities. Little 
or no myotonia remains.
100 ag,/ACTf*/2fc hrs. 5-17-50 to 5-29-50
fie showed no favorable response to 
treatment.
Date
8-1
8—1
Mature of Specimen Treatment
Control
Control
none
m m
"lxcreilon'''"1“*,‘ 
per 2k hours
,72k m*
1,12 mg.
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PATIENT #7
Age
Sex
Disease
Duration
Symptom
Treatment
Response
Patient H.D.
26 years 
Male
Dystrophia %otonioa 
9 years
He showed early cataracts and testicular 
atrophy, generalised moderate muscular 
atrophy and marked general myotonia.
100 mg. ACTB/2k hra, h-22-50 to 5-2*50
100 mg. Cortisone/^ hrs. 3-26-50 to li-12-50
He gained weight, had a feeling of well­
being, marked iagjroveaent of myotonia, 
but no change in strength.
Date Nature of Specimen Treatment IxwTriSon per 2U hours
7-21*
7-2*4
Control
Control
none
none
1.32 mg. 
1.02 mg.
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PATIENT #8
Patient
Age
Sex
Disease
Duration
Symptom®
Treatment
Response
A .S .
36 years 
Hale
l$rotonia Congenita 
22 years
He showed general nyotonia, but no 
atrophy or visceral dystrophies.
ACTB 6 days 100 «g./2U brs. 
h days 200 rag./2l* hr s.
Only on 200 mg./2h hrs. was any marked 
adrenal response noted. Slight inqprove- 
ment of the nyotonia resulted.
Date* “^ ai'ufe"’ of^SpeciSin' Treatment Excretion 
per 2h hours
7-22 Control none 2.53
PATIENT #9
Patient C.F.
Sax Female
Aga 1*8 years
Disease Rheumatoid Arthritis
Duration 15 year®
Symptom The small joints of the hands and feet, 
the joints of the upper extremity and 
of the ankle are chiefly affected. 
Admission sedimentation rate was 35 mm, 
by the Wintrobe method. Bar condition 
is only moderate severe.
Treatment 300 mg,/2h hrs. XM dehydroisoandros- 
terone 2-13-50 to 2-19-50 
1 gr&vs/2h boors. Oral dehydroisoandros 
terone 2-21-50 to 2-23-50.
Response She showed no clinical response, no 
significant change in sedimentation 
rate, no evidence of adrenocortical 
response nor of androgenic effect*
Date ■ Nature of Specimen
Excretion 
Treatment per 2k hours
2-7 Control non® 1.50 mg.
1.1*6 mg.
2-13 Treated 300 mg./2i* hr. 2.1tl mg. 
dehydroisoand- 2.57 mg. 
rosterone
2-15 Treated as above 2*66 mg.
2.57 mg.
2-17 Treated as above 1.92 mg.
,866 mg.
2-10 Treated as above .866 mg.
*863 mg*
2-21 Treated 1 gm./2U hr. .763 mg. 
dehydroisoand- .951 mg. 
rosterone - oral
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Age
Sex
Disease
Duration
Symptoms
P atien t
Treatment
Response
PATIENT #10 
R.B.
k6year®
Hal®
Rheumatoid Arthritis 
12 years
His handsj feet, knees and elbows are
deformed. He was admitted with acute 
■arthritis of seek, shoulders and 
wrist and la acute pain. His sedi­
mentation rate by WiatrObe method 
was 1)2ram.
300 rag./2l) hrs. 2M dehydrolsoandros- 
terone l-2lt-50 to 1-20-50. 300 mg./
2h hrs. Pregnenolone 2-20-50 to 2-28-50
On artison© therapy he experienced no 
improvement in clinical arthritis, no 
evidence of androgenic effect or of 
interference with liver function. There 
was no significant change in sedimenta­
tion rate. On dehydroisoandrosterone 
therapy there was no evidence of 
improvement.
Date Mature of Specimen Treatment
Secretion 
per 2 hhours
Unknown *1 Control non® 1.31 ng./Liter *2 
.996
2-1 Control non© •317mg. 
.263 ng.
2-2 Control none .1)25 mg. 
.371) mg.
2-3 Control none .768 mg.
2-1* Control none .527 rag.
*1 See explanation at end of this section 
#2 Volume unknown
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PATIENT #10 
(Continued)
Bate Nature of Specimen Treatment
IxoreSTon 
per 22* hours
2-22. Treatment 300 ng./2i* hr s.
Artlsone
1.35 mg. 
1.06 mg.
2-22* Treated as above 1.10 mg.
1.01 mg.
2-26 Treated as above 1.2*8 mg.
2-28 treated as above 1.68 mg. 
1.30 mg.
3-2 Control none 1.25 mg.
2.92 mg.
3*4* Control none 1.82 ag. 
1.8? mg.
lo date *1 Control .> non© •39kmg. 1 L 
.338 mg. 1 L
1-25 Treated 300 mg./2l* hr®.
dehydroisoand-
rosterone
3.97 mg.
1-26 Treated as above non©
demonstrated
1-2? Treated as above 1.30 mg. 
.902 mg.
1-28 Treated as above •581 mg. 
.372 mg.
1-29 Control
discontinued 1/20
non® •hh9mg. 
1.10 mg. el
1-30 Control none .726 mg. 
.1*67 mg.
1-31 Control none .756 mg.
.720 ag.
*1 See explanation at the end of this s@ot.ion
»2 Vol. anddate of this sample are not known. See discussion of samples 1-25-50 to 1-29-50 at the end of this section.
3?
Age
Sex
Bisease
Duration
Symptoms
\ ’
Patient
treatment 300 mg./2U hows pregnenolone
3-14-50 to 3-20-50
Response He showed no response to therapy.
Date Uature of Specimen Treatment
T&eretibh 
per $khours
3-19 Control none 1.25 mg. 
1.16 mg.
3-lh Treated 300 I^PT e 0^0#«»' 
nenolone/2l* hrs
3.03 mg. 
. 3.03 mg.
3-17 Treated\ as above 9.UU mg. *1 9.27 mg.
3-19 Treated as above •718 mg. 
.671 mg.
3-22 Control none 1.32 mg.
w . v .
30 years
' •' •. *  .
Male
Disseminated lupus ejythem&tosus 
6 years
He has low grade fever, chronic, in­
durated, secondarily infected facial 
rash, marked cervical lyaphoadenopathy, 
and pleuritic chest pain. He showed 
no evidence of renal damage.
M TISt? #11
*1 See explanation at end of this section
3a
Diseuagion of difficulties Seven of the Individual samples 
Included In this series gave readings which were so high as to he 
unbelievable la relation to adjacent samples or in some oases to 
samples taken from the same urine. No explanation for this variance 
is evident since the procedure followed in every case was, as such as 
we could make it so, identical. The obviously erroneous values are 
Indicated in the tables of results.
Samples 1-25-50 to 1-29-50 for the patient, R.D., showed heavy 
precipitate in the dried extract. There is no likely explanation for 
this precipitate and no attempt was made to identify it.
mt m m  S
Patient ciaaaae
Cllnieal 
E»rapy* Hespone©
‘T ir r a E O T O T n » ttW
arostDent treatment
JS I)ystl*Ophia
ayoionioa.
AC®! #♦ 3.76 t© *68f 1 4 0
IS Oystrophla
Syotonloa
Ion© 1*73 to i#9t
® Systrophia
Hyo'toHea
ACTS ♦*♦ *31*8 to .736 2 4 1
US fjywfepopttta A m .172 1.78
OS Dystrophia
Myotonies
iOMt
I.6S
m BystropM®
Kyotooi©*
ACT 90 *917
m DyitsfopMa
Hyotoaiea
AC®! 4MH* 
CkjapoanS S
1*17
m Hyotonia
Congenita
AC®! * 2 .S3
m Hl»ymatold
A rteritis
Dehydro- sou©
Iseandroa-
tsrons
1.63 2 .62 to 
.677
m sus«aw i6
A rteritis
Artisan© none 1.05 to 1*1# 4 9 0  to 
*768
m mWfMQwla
A rthritis
B©!sydro» non©
isoandros-
t©KW»
4 7 6  to 1 4 0
m
*  i n
Oistottl* PwtgM®o3u« non©
sates! lupwsi
©rytetaaeteeaa
lS rb w M »aF lS ^ »te^ a
. 6 *  to 3 .0 J
♦♦ llodsiwte iappav«»nt la a^tonla
+•*•♦ ilarted improvement In myotonia
00 So ssy©tar&& remain©:! at tta© of troataaat
1*0
Discussion and conclusions* The normal rang® of eortin excretion 
as determined by this procedure was .90 to 1.30 mg./2i* hours. Five norm­
al determinations were made, A larger number of determination® would 
undoubtedly haw# resulted in a wider range.
The control levels of the patients with dystrophia myotonica 
and ayotonia congenita varied from .37 to 2.69 mg./2i* hours. Four 
were* below the estimated normal, one within the normal range and three 
above normal. There was more day to day variation than is the case in 
the normals presented in the literature.
In three patients, JK, OB, BB, treatment levels of eortin excre­
tion following ACTH therapy were measured. In each, a very marked 
increase in eortin excretion was noted. This is not surprising in 
vi m of the fact that the known function of ACTH is to stimulate the 
production of the adrenal cortical hormones. It also demonstrated 
that, whether or not the adrenal cortex is involved in the etiology 
of dystrophia myotonies and myotonia congenita, these patients have 
ample adrenal cortical tissue to display a marked response to ACTS.
Five, JK, OB, DB, IS), AS, of the six patients treated with ACTH 
showed some improvement In myotonia. The disease was too far 
advanced in the sixth, IE, for any ayotonia to remain. Improvement 
in strength was not noted.
On the basis of these observations, the following conclusions 
seem warranted*
(1). These data do not warrant aiy inference that the adrenal 
cortex is functionally incapacitated in this disease.
(2). In each of the patients whose urine was examined after ACTH
h i
therapy, the adrenal cortex was sufficiently normal to give a marked 
response to the trophic hormone*
(3)* There is considerable reason to hope from this experiment 
that ACTE may offer some benefit in the treatment of these two diseased 
states* The on® patient who was treat®! with Compound E showed a 
clinical response similar to that which he demonstrated on ACTH.
The two patients with rheumatoid arthritis, RA and CF and one 
with disseminated lupus erythematosus, W,  who were treated with 
dehydroisoandrosterone and pregnenolone showed no clinical response to 
these hormones.
However, with both the pregnenolone series and one of the two 
dehydroisoandrosterone series, the excretion of formaldehydogenic sub­
stances increased. These increases followed a characteristic pattern 
in three of the four series. At first, a marked increase in cortin 
excretion was noted. Then there was a gradual decline to subnormal 
levels, even while the administration was continued.
Four methods of explaining these responses present themselves*
First, that the pregnenolone and dehydroisandrosterane acted as a 
precursor for the adrenal cortical hormones. This explanation seems 
highly improbable in that none of the three patients showed a clinical 
improvement.
Secondly, that the variation is due to the variability noted 
above for control samples of persona suffering from these diseases*
This explanation also seems inprobable in rim of the characteristic 
pattern of the excretory levels following administration.
Thirdly, that the pregnenolone and dehydroisoandrosterone were
k2
converted into steroids with the characteristic group of the cortin 
compounds, but that the metabolic pathway traversed did not include any 
of the active hormones. This theory, in addition to being consistent 
with the clinical and chemical observations, might explain the tendency 
noted above for an initial increase to be followed by a gradual 
decline to subnormal level.
Fourthly, the large doses of hormones administered may have produced, 
a stress on the adrenal cortex. The initial stimulation followed by a 
decline to subnormal levels is typical of the secretion pattern 
following other stressful situations.
k3
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